SCHEDULE 13G/A 0000902664-25-000981 0001910456 XXXXXXXX LIVE 2 Common Stock, par value $0.000005 per share 12/31/2025 0001357874 PRECISION BIOSCIENCES INC 74019P207 302 EAST PETTIGREW STREET SUITE A-100 DURHAM NC 27701 Rule 13d-1(c) Lynx1 Capital Management LP DE 0.00 993913.00 0.00 993913.00 993913.00 N 4.1 PN Weston Nichols X1 0.00 993913.00 0.00 993913.00 993913.00 N 4.1 IN PRECISION BIOSCIENCES INC 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701 This statement is filed by: (i) Lynx1 Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the "Lynx1 Fund"), with respect to the shares of common stock, par value $0.000005 per share ("Common Stock"), of Precision BioSciences, Inc., a Delaware corporation (the "Company"), directly held by the Lynx1 Fund; and (ii) Mr. Weston Nichols ("Mr. Nichols"), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Lynx1 Fund. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051 Weston Nichols c/o Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051 Investment Manager - Delaware Mr. Nichols - United States of America Y The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 24,071,751 shares of Common Stock outstanding, which is the sum of (i) 10,815,000 shares of Common Stock issued in the offering described in the Company's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission (the "SEC") on November 12, 2025 and (ii) 13,256,751 shares of Common Stock outstanding as of October 29, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 3, 2025. 4.1% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. N Y N See Item 2(a). Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Lynx1 Capital Management LP /s/ Weston Nichols 02/17/2026 Weston Nichols /s/ Weston Nichols 02/17/2026